Safety and Effectiveness of AZD4877 in Japanese Cancer Patients
Author Information
Author(s): Taito Esaki, Takashi Seto, Hiroshi Ariyama, Shuji Arita, Chinatsu Fujimoto, Koichiro Tsukasa, Takuro Kometani, Kaname Nosaki, Fumihiko Hirai, Katsuro Yagawa
Primary Institution: National Kyushu Cancer Center
Hypothesis
This study aims to evaluate the safety, pharmacokinetic profile, maximum tolerated dose, and efficacy of AZD4877 in Japanese patients with solid tumors.
Conclusion
AZD4877 up to doses of 25 mg was well tolerated in Japanese patients, but there was little evidence of clinical efficacy.
Supporting Evidence
- 18 out of 21 enrolled patients received at least one dose of AZD4877.
- The most commonly reported adverse events were fatigue and nausea, affecting 39% of patients each.
- The best response to AZD4877 was stable disease in five of 16 evaluable patients.
Takeaway
Doctors tested a new cancer drug called AZD4877 on Japanese patients, and while it didn't seem to help much, the patients didn't have serious side effects.
Methodology
This was a Phase I, open-label, dose-escalation study where AZD4877 was administered intravenously to patients with advanced solid tumors.
Limitations
The maximum tolerated dose was not defined in this population, and the study had a small sample size.
Participant Demographics
The mean age of patients was 62.7 years, with 61.1% being female and a variety of solid tumor types represented.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website